Cardiotoxicity of Targeted Therapies in Children with Haematological Malignancies and Solid Tumors

Steliarova-Foucher, E.; Colombet, M.; Ries, L.A.G.; Moreno, F.; Dolya, A.; Bray, F.; Hesseling, P.; Shin, H.Y.; Stiller, C.A.; Bouzbid, S.; Hamdi-Cherif, M.; Hablas, A.; Chirpaz, E.; Buziba, N.; Chesumbai, G.C.; Manraj, S.S.; Reynders, D.; Wabinga, H.R.; Chokunonga, E.; Moreno, F.; Lima, C.A.; Asturian, L.C.; de Oliveira, J.C.; de Aquino, J.A.P.; Gallagher, S.M.V.; Uribe, C.J.; Bravo, L.E.; Yepez, C.M.C.; Torres, A.G.; Galán, A.Y.H.; Martinez, R.F.C.; Castillo, C.J.C.; Mendoza, A.M.; Cueva, A.P.; Hanchard, B.; Fajardo-Gutiérrez, A.; Zavala Zegarra, D.E.; Barrios, E.; Nikiforuk, C.; Woods, R.; Turner, D.; MacIntyre, M.; Corriveau, A.; Navaneelan, T.; Bertrand, C.; Stuart-Panko, H.; Wilson, R.J.; Kosary, C.; Shen, X.; Brockhouse, J.; Yee, G.A.; Mitchell, T.C.; Snipes, K.; West, D.; Rao, C.; Bolick, S.; Rycroft, R.K.; Mueller, L.; Zheng, Y.; Dosch, K.; Brown, H.; Vargas, A.; Levin, G.M.; Bayakly, R.; Johnson, C.; Shen, T.; Ruppert, L.; Lynch, C.F.; Lai, S.M.; Tucker, T.C.; Wu, X.C.; Schwenn, M.; Stern, K.; Gershman, S.; Copeland, G.; Bushhouse, S.; Rogers, D.B.; Jackson Thompson, J.; Lemons, D.; Frederick, S.; Harris, J.A.; Riddle, B.; Stroup, A.; Wiggins, C.; Schymura, M.J.; Giljahn, L.K.; Sheikh, A.; Schubert, S.; Aldinger, W.; Fulton, J.P.; Whiteside, M.; Nogueira, L.; Sweeney, C.; Johnson, A.; Martin, J.; Farley, S.; Harrelson, D.; Malicki, R.; Espinoza, J.R.; Hernandez, B.Y.; Abulfateh, N.; Wang, N.; Ngan, R.K.C.; Lingegowda, K.B.; Swaminathan, R.; Koyande, S.S.; Silverman, B.; Ozasa, K.; Kanemura, S.; Soda, M.; Miyashiro, I.; Shibata, A.; Nimri, O.; Won, Y.J.; Kim, C.H.; Hong, N.S.; Nam, H.S.; Kweon, S.; Kim, W.C.; Huh, J.S.; Jung, K.W.; Yoo, C.I.; Elbasmy, A.; Laudico, A.V.; Lumague, M.R.; AlMutlag, H.; Buasom, R.; Srisukho, S.; Tanabodee, J.; Wiangnon, S.; Pongnikorn, D.; Sriplung, H.; Dirican, O.; Eser, S.; Le Hoang, M.; Hackl, M.; Zborovskaya, A.; Dimitrova, N.; Valerianova, Z.; Sekerija, M.; Pavlou, P.; Dušek, M.; Mägi, M.; Clavel, J.; Lacour, B.; Guizard, A.V.; Bouvier, V.; Troussard, X.; Woronoff, A.S.; Tretarre, B.; Colonna, M.; Molinié, F.; Bara, S.; Velten, M.; Marrer, E.; Ganry, O.; Grosclaude, P.; Kaatsch, P.; Zeissig, S.R.; Holleczek, B.; Katalinic, A.; Jakab, Z.; Birgisson, H.; Walsh, P.M.; Mangone, L.; Merletti, F.; Magoni, M.; Mangone, L.; Ferretti, S.; Serraino, D.; Spagnoli, G.; Fusco, M.; Michiara, M.; Tumino, R.; Falcini, F.; Sensi, F.; Tisano, F.; Piffer, S.; Stracci, F.; Tagliabue, G.; Smailyte, G.; Agius, D.; Visser, O.; Ursin, G.; Didkowska, J.; Trojanowski, M.; Wojciechowska, U.; Forjaz de Lacerda, G.; Silva, M.A.; Laranja, P.J.; da Costa Miranda, A.; Kaiserova, E.; Primic, Ž.M.; Peris-Bonet, R.; Vicente, R.M.L.; Almar, M.E.; Quirós, G. J.R.; Ramos, M.M.; Errezola Saizar, M.; Alemán Herrera, A.; Díaz, G.J.M.; Marcos-Gragera, R.; Sanchez-Perez, M.J.; Ardanaz, A.E.; Galceran, J.; Klint, A.; Kuehni, C.E.; Bouchardy, C.; Levi, F.; Bordoni, A.; Konzelmann, I.; Rohrmann, S.; Stiller, C.A.; Gavin, A.T.; Brewster, D.H.; Phung, H.; Rushton, S.; Guthridge, S.; Aitken, J.; D’Onise, K.; Venn, A.; Farrugian, H.; Threlfall, T.J.; Laumond, S.; Yen Kai Sun, L.; Hendrix, J.; Ballantine, K.; Colombet, M.; Dolya, A.; Masuyer, E.; Steliarova-Foucher, E. International incidence of childhood cancer, 2001–10: a population-based registry study. Lancet Oncol., 2017, 18(6), 719-731.
[http://dx.doi.org/10.1016/S1470-2045(17)30186-9] [PMID: 28410997]

Sherry, L.M.; Xu, J.; Kochanek, K.D.; Arias, E.; Tejada-Vera, B. Deaths: Final Data for 2018. National Vital Statistics Reports, 2018, 69(13)

Howlader, N.; Noone, A.M.; Krapcho, M. SEER Cancer Statistics Review, 1975–2013; National Cancer Institute: Bethesda, MD, 2016.

Mertens, A.C.; Liu, Q.; Neglia, J.P.; Wasilewski, K.; Leisenring, W.; Armstrong, G.T.; Robison, L.L.; Yasui, Y. Cause-specific late mortality among 5-year survivors of childhood cancer: The childhood cancer survivor study. J. Natl. Cancer Inst., 2008, 100(19), 1368-1379.
[http://dx.doi.org/10.1093/jnci/djn310] [PMID: 18812549]

Oeffinger, K.C.; Mertens, A.C.; Sklar, C.A. Chronic health conditions in adult survivors of childhood cancer. Oncol. Times, 2007, 29(1), 26.
[http://dx.doi.org/10.1097/01.COT.0000265629.30194.8e]

Mulrooney, D.A.; Yeazel, M.W.; Kawashima, T.; Mertens, A.C.; Mitby, P.; Stovall, M.; Donaldson, S.S.; Green, D.M.; Sklar, C.A.; Robison, L.L.; Leisenring, W.M. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ, 2009, 339(1), b4606.
[http://dx.doi.org/10.1136/bmj.b4606] [PMID: 19996459]

Armstrong, G.T.; Chen, Y.; Yasui, Y.; Leisenring, W.; Gibson, T.M.; Mertens, A.C.; Stovall, M.; Oeffinger, K.C.; Bhatia, S.; Krull, K.R.; Nathan, P.C.; Neglia, J.P.; Green, D.M.; Hudson, M.M.; Robison, L.L. Reduction in late mortality among 5-year survivors of childhood cancer. N. Engl. J. Med., 2016, 374(9), 833-842.
[http://dx.doi.org/10.1056/NEJMoa1510795] [PMID: 26761625]

Gibson, T.M.; Mostoufi-Moab, S.; Stratton, K.L.; Barnea, D.; Chow, E.J.; Donaldson, S.S.; Howell, R.M.; Hudson, M.M.; Leisenring, W.M.; Mahajan, A.; Nathan, P.C.; Ness, K.K.; Sklar, C.A.; Tonorezos, E.S.; Weldon, C.B.; Wells, E.M.; Yasui, Y.; Armstrong, G.T.; Robison, L.L.; Oeffinger, K.C. Temporal patterns in the risk of chronic health conditions among survivors of childhood cancer diagnosed 1970-1999: A report from the childhood cancer survivor study. Lancet Oncol., 2018, 19(12), 1590-1601.

Mulrooney, D.A.; Armstrong, G.T.; Huang, S.; Ness, K.K.; Ehrhardt, M.J.; Joshi, V.M.; Plana, J.C.; Soliman, E.Z.; Green, D.M.; Srivastava, D.; Santucci, A.; Krasin, M.J.; Robison, L.L.; Hudson, M.M. Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy. Ann. Intern. Med., 2016, 164(2), 93-101.
[http://dx.doi.org/10.7326/M15-0424] [PMID: 26747086]

Hunt, S.A.; Abraham, W.T.; Chin, M.H.; Feldman, A.M.; Francis, G.S.; Ganiats, T.G.; Jessup, M.; Konstam, M.A.; Mancini, D.M. Focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults. Circulation, 2009, 119, e391-e479.

Denlinger, C.S.; Sanft, T.; Baker, K.S.; Broderick, G.; Demark-Wahnefried, W.; Friedman, D.L.; Goldman, M.; Hudson, M.; Khakpour, N.; King, A.; Koura, D.; Lally, R.M.; Langbaum, T.S.; McDonough, A.L.; Melisko, M.; Montoya, J.G.; Mooney, K.; Moslehi, J.J.; O’Connor, T.; Overholser, L.; Paskett, E.D.; Peppercorn, J.; Pirl, W.; Rodriguez, M.A.; Ruddy, K.J.; Silverman, P.; Smith, S.; Syrjala, K.L.; Tevaarwerk, A.; Urba, S.G.; Wakabayashi, M.T.; Zee, P.; McMillian, N.R.; Freedman-Cass, D.A. Survivorship, Version 2.2018, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw., 2018, 16(10), 1216-1247.
[http://dx.doi.org/10.6004/jnccn.2018.0078] [PMID: 30323092]

Lipshultz, S.E.; Adams, M.J.; Colan, S.D.; Constine, L.S.; Herman, E.H.; Hsu, D.T.; Hudson, M.M.; Kremer, L.C.; Landy, D.C.; Miller, T.L.; Oeffinger, K.C.; Rosenthal, D.N.; Sable, C.A.; Sallan, S.E.; Singh, G.K.; Steinberger, J.; Cochran, T.R.; Wilkinson, J.D. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation, 2013, 128(17), 1927-1995.
[http://dx.doi.org/10.1161/CIR.0b013e3182a88099] [PMID: 24081971]

Ryan, T.D.; Nagarajan, R.; Godown, J. Cardiovascular toxicities in pediatric cancer survivors. Cardiol. Clin., 2019, 37(4), 533-544.
[http://dx.doi.org/10.1016/j.ccl.2019.07.002] [PMID: 31587793]

Moslehi, J.J. Cardiovascular toxic effects of targeted cancer therapies. N. Engl. J. Med., 2016, 375(15), 1457-1467.
[http://dx.doi.org/10.1056/NEJMra1100265] [PMID: 27732808]

Neilan, T.G.; Rothenberg, M.L.; Amiri-Kordestani, L.; Sullivan, R.J.; Steingart, R.M.; Gregory, W.; Hariharan, S.; Hammad, T.A.; Lindenfeld, J.; Murphy, M.J.; Moslehi, J.J. Myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action. Oncologist, 2018, 23(8), 874-878.
[http://dx.doi.org/10.1634/theoncologist.2018-0157] [PMID: 29802220]

Kantarjian, H.M.; DeAngelo, D.J.; Stelljes, M.; Martinelli, G.; Liedtke, M.; Stock, W.; Gökbuget, N.; O’Brien, S.; Wang, K.; Wang, T.; Paccagnella, M.L.; Sleight, B.; Vandendries, E.; Advani, A.S. Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med., 2016, 375(8), 740-753.
[http://dx.doi.org/10.1056/NEJMoa1509277] [PMID: 27292104]

Available from: https://ec.europa.eu/health/documents/communityregister/2017/20170629138094/anx_138094_el.pdf

Pennesi, E.; Michels, N.; Brivio, E.; van der Velden, V.H.J.; Jiang, Y.; Thano, A.; Ammerlaan, A.J.C.; Boer, J.M.; Beverloo, H.B.; Sleight, B.; Chen, Y.; Vormoor-Bürger, B.; Rives, S.; Bielorai, B.; Rössig, C.; Petit, A.; Rizzari, C.; Engstler, G.; Starý, J.; Bautista Sirvent, F.J.; Chen-Santel, C.; Bruno, B.; Bertrand, Y.; Rialland, F.; Plat, G.; Reinhardt, D.; Vinti, L.; Von Stackelberg, A.; Locatelli, F.; Zwaan, C.M. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: Results from a phase II trial. Leukemia, 2022, 36(6), 1516-1524.
[http://dx.doi.org/10.1038/s41375-022-01576-3] [PMID: 35468945]

O’Brien, M.M.; Ji, L.; Shah, N.N.; Rheingold, S.R.; Bhojwani, D.; Yuan, C.M.; Xu, X.; Yi, J.S.; Harris, A.C.; Brown, P.A.; Borowitz, M.J.; Militano, O.; Kairalla, J.; Devidas, M.; Raetz, E.A.; Gore, L.; Loh, M.L.; Phase, I.I.; Phase, I.I. Trial of Inotuzumab Ozogamicin in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia: Children’s oncology group protocol AALL1621. J. Clin. Oncol., 2022, 40(9), 956-967.
[http://dx.doi.org/10.1200/JCO.21.01693] [PMID: 35007127]

Giudice, V.; Vecchione, C.; Selleri, C. Cardiotoxicity of novel targeted hematological therapies. Life, 2020, 10(12), 344.
[http://dx.doi.org/10.3390/life10120344] [PMID: 33322351]

Silva, P.N.; Valente, P.M.S.; Castilho, S.R. Monoclonal-induced cardiotoxicity in patients with non-Hodgkin’s lymphoma and breast cancer: A retrospective study in an oncology clinic. J. Oncol. Pharm. Pract., 2022.
[http://dx.doi.org/10.1177/10781552221098426] [PMID: 35542978]

Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera

McAtee, C.L.; Lubega, J.; Underbrink, K.; Curry, K.; Msaouel, P.; Barrow, M.; Muscal, E.; Lotze, T.; Srivaths, P.; Forbes, L.R.; Allen, C.; Bernhardt, M.B. Association of Rituximab use with adverse events in children, adolescents, and young adults. JAMA Netw. Open, 2021, 4(2), e2036321.
[http://dx.doi.org/10.1001/jamanetworkopen.2020.36321] [PMID: 33533931]

Darvishi, B.; Farahmand, L.; Jalili, N.; Majidzadeh-A, K. Blinatumomab provoked fatal heart failure. Int. Immunopharmacol., 2016, 41, 42-46.
[http://dx.doi.org/10.1016/j.intimp.2016.10.017] [PMID: 27816725]

Mahadeo, K.M.; Khazal, S.J.; Abdel-Azim, H.; Fitzgerald, J.C.; Taraseviciute, A.; Bollard, C.M.; Tewari, P.; Duncan, C.; Traube, C.; McCall, D.; Steiner, M.E.; Cheifetz, I.M.; Lehmann, L.E.; Mejia, R.; Slopis, J.M.; Bajwa, R.; Kebriaei, P.; Martin, P.L.; Moffet, J.; McArthur, J.; Petropoulos, D.; O’Hanlon Curry, J.; Featherston, S.; Foglesong, J.; Shoberu, B.; Gulbis, A.; Mireles, M.E.; Hafemeister, L.; Nguyen, C.; Kapoor, N.; Rezvani, K.; Neelapu, S.S.; Shpall, E.J. Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat. Rev. Clin. Oncol., 2019, 16(1), 45-63.
[http://dx.doi.org/10.1038/s41571-018-0075-2] [PMID: 30082906]

Grupp, S.A.; Kalos, M.; Barrett, D.; Aplenc, R.; Porter, D.L.; Rheingold, S.R.; Teachey, D.T.; Chew, A.; Hauck, B.; Wright, J.F.; Milone, M.C.; Levine, B.L.; June, C.H. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med., 2013, 368(16), 1509-1518.
[http://dx.doi.org/10.1056/NEJMoa1215134] [PMID: 23527958]

Maude, S.L.; Frey, N.; Shaw, P.A.; Aplenc, R.; Barrett, D.M.; Bunin, N.J.; Chew, A.; Gonzalez, V.E.; Zheng, Z.; Lacey, S.F.; Mahnke, Y.D.; Melenhorst, J.J.; Rheingold, S.R.; Shen, A.; Teachey, D.T.; Levine, B.L.; June, C.H.; Porter, D.L.; Grupp, S.A. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med., 2014, 371(16), 1507-1517.
[http://dx.doi.org/10.1056/NEJMoa1407222] [PMID: 25317870]

June, C.H.; Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med., 2018, 379(1), 64-73.
[http://dx.doi.org/10.1056/NEJMra1706169] [PMID: 29972754]

Chen, Z.I.; Ai, D.I. Cardiotoxicity associated with targeted cancer therapies. Mol. Clin. Oncol., 2016, 4(5), 675-681.
[http://dx.doi.org/10.3892/mco.2016.800] [PMID: 27123262]

Wang, J.; Mou, N.; Yang, Z.; Li, Q.; Jiang, Y.; Meng, J.; Liu, X.; Deng, Q. Efficacy and safety of humanized anti‐CD19‐CAR‐T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia Br. J. Haematol., 2020, 191(2), 212-222.
[http://dx.doi.org/10.1111/bjh.16623] [PMID: 32232846]

Ganatra, S.; Parikh, R.; Neilan, T.G. Cardiotoxicity of immune therapy. Cardiol. Clin., 2019, 37(4), 385-397.
[http://dx.doi.org/10.1016/j.ccl.2019.07.008] [PMID: 31587780]

Pathan, N.; Hemingway, C.A.; Alizadeh, A.A.; Stephens, A.C.; Boldrick, J.C.; Oragui, E.E.; McCabe, C.; Welch, S.B.; Whitney, A.; O’Gara, P.; Nadel, S.; Relman, D.A.; Harding, S.E.; Levin, M. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet, 2004, 363(9404), 203-209.
[http://dx.doi.org/10.1016/S0140-6736(03)15326-3] [PMID: 14738793]

Lee, D.W.; Santomasso, B.D.; Locke, F.L.; Ghobadi, A.; Turtle, C.J.; Brudno, J.N.; Maus, M.V.; Park, J.H.; Mead, E.; Pavletic, S.; Go, W.Y.; Eldjerou, L.; Gardner, R.A.; Frey, N.; Curran, K.J.; Peggs, K.; Pasquini, M.; DiPersio, J.F.; van den Brink, M.R.M.; Komanduri, K.V.; Grupp, S.A.; Neelapu, S.S. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant., 2019, 25(4), 625-638.
[http://dx.doi.org/10.1016/j.bbmt.2018.12.758] [PMID: 30592986]

Alvi, R.M.; Frigault, M.J.; Fradley, M.G.; Jain, M.D.; Mahmood, S.S.; Awadalla, M.; Lee, D.H.; Zlotoff, D.A.; Zhang, L.; Drobni, Z.D.; Hassan, M.Z.O.; Bassily, E.; Rhea, I.; Ismail-Khan, R.; Mulligan, C.P.; Banerji, D.; Lazaryan, A.; Shah, B.D.; Rokicki, A.; Raje, N.; Chavez, J.C.; Abramson, J.; Locke, F.L.; Neilan, T.G. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J. Am. Coll. Cardiol., 2019, 74(25), 3099-3108.
[http://dx.doi.org/10.1016/j.jacc.2019.10.038] [PMID: 31856966]

Lefebvre, B.; Kang, Y.; Smith, A.M.; Frey, N.V.; Carver, J.R.; Scherrer-Crosbie, M. Cardiovascular effects of CAR T-cell therapy. JACC: CardioOncology, 2020, 2(2), 193-203.
[http://dx.doi.org/10.1016/j.jaccao.2020.04.012] [PMID: 32776016]

Shalabi, H.; Sachdev, V.; Kulshreshtha, A.; Cohen, J.W.; Yates, B.; Rosing, D.R.; Sidenko, S.; Delbrook, C.; Mackall, C.; Wiley, B.; Lee, D.W.; Shah, N.N. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. J. Immunother. Cancer, 2020, 8(2), e001159.
[http://dx.doi.org/10.1136/jitc-2020-001159] [PMID: 32883871]

Burstein, D.S.; Maude, S.; Grupp, S.; Griffis, H.; Rossano, J.; Lin, K. Cardiac profile of chimeric antigen receptor T-cell therapy in children: A single-institution experience. Biol. Blood Marrow Transplant., 2018, 24(8), 1590-1595.
[http://dx.doi.org/10.1016/j.bbmt.2018.05.014] [PMID: 29772353]

Fitzgerald, J.C.; Weiss, S.L.; Maude, S.L.; Barrett, D.M.; Lacey, S.F.; Melenhorst, J.J.; Shaw, P.; Berg, R.A.; June, C.H.; Porter, D.L.; Frey, N.V.; Grupp, S.A.; Teachey, D.T. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit. Care Med., 2017, 45(2), e124-e131.
[http://dx.doi.org/10.1097/CCM.0000000000002053] [PMID: 27632680]

Kochenderfer, J.N.; Somerville, R.P.T.; Lu, T.; Shi, V.; Bot, A.; Rossi, J.; Xue, A.; Goff, S.L.; Yang, J.C.; Sherry, R.M.; Klebanoff, C.A.; Kammula, U.S.; Sherman, M.; Perez, A.; Yuan, C.M.; Feldman, T.; Friedberg, J.W.; Roschewski, M.J.; Feldman, S.A.; McIntyre, L.; Toomey, M.A.; Rosenberg, S.A. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T-cells are associated with high serum Interleukin-15 levels. J. Clin. Oncol., 2017, 35(16), 1803-1813.
[http://dx.doi.org/10.1200/JCO.2016.71.3024] [PMID: 28291388]

Wang, S.Y.; Zhao, L.N.; Cheng, H.; Shi, M.; Chen, W.; Qi, K.M.; Sun, C.; Wang, X.; Cao, J.; Xu, K.L. Long-term safety and activity of humanized CD19 chimeric antigen receptor T cells for children and young adults with relapsed/refractory acute lymphoblastic leukemia. Zhonghua Xue Ye Xue Za Zhi, 2022, 43(7), 557-561.
[PMID: 36709132]

Lee, D.W.; Kochenderfer, J.N.; Stetler-Stevenson, M.; Cui, Y.K.; Delbrook, C.; Feldman, S.A.; Fry, T.J.; Orentas, R.; Sabatino, M.; Shah, N.N.; Steinberg, S.M.; Stroncek, D.; Tschernia, N.; Yuan, C.; Zhang, H.; Zhang, L.; Rosenberg, S.A.; Wayne, A.S.; Mackall, C.L. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet, 2015, 385(9967), 517-528.
[http://dx.doi.org/10.1016/S0140-6736(14)61403-3] [PMID: 25319501]

Davila, M.L.; Riviere, I.; Wang, X.; Bartido, S.; Park, J.; Curran, K.; Chung, S.S.; Stefanski, J.; Borquez-Ojeda, O.; Olszewska, M.; Qu, J.; Wasielewska, T.; He, Q.; Fink, M.; Shinglot, H.; Youssif, M.; Satter, M.; Wang, Y.; Hosey, J.; Quintanilla, H.; Halton, E.; Bernal, Y.; Bouhassira, D.C.G.; Arcila, M.E.; Gonen, M.; Roboz, G.J.; Maslak, P.; Douer, D.; Frattini, M.G.; Giralt, S.; Sadelain, M.; Brentjens, R. Efficacy and toxicity management of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia. Sci. Transl. Med., 2014, 6(224), 224ra25.
[http://dx.doi.org/10.1126/scitranslmed.3008226] [PMID: 24553386]

Yáñez, L.; Sánchez-Escamilla, M.; Perales, M.A. CAR T-cell toxicity: Current management and future directions. HemaSphere, 2019, 3(2), e186.
[http://dx.doi.org/10.1097/HS9.0000000000000186] [PMID: 31723825]

Kymriah-Epar-Product-Information. Available from: https://www.ema.europa.eu/documents/product-information/kymriah- epar-product-information_en.pdf

Schuster, S.J.; Bishop, M.R.; Tam, C.S.; Waller, E.K.; Borchmann, P.; McGuirk, J.P.; Jäger, U.; Jaglowski, S.; Andreadis, C.; Westin, J.R.; Fleury, I.; Bachanova, V.; Foley, S.R.; Ho, P.J.; Mielke, S.; Magenau, J.M.; Holte, H.; Pantano, S.; Pacaud, L.B.; Awasthi, R.; Chu, J.; Anak, Ö.; Salles, G.; Maziarz, R.T. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl. J. Med., 2019, 380(1), 45-56.
[http://dx.doi.org/10.1056/NEJMoa1804980] [PMID: 30501490]

Maude, S.L.; Laetsch, T.W.; Buechner, J.; Rives, S.; Boyer, M.; Bittencourt, H.; Bader, P.; Verneris, M.R.; Stefanski, H.E.; Myers, G.D.; Qayed, M.; De Moerloose, B.; Hiramatsu, H.; Schlis, K.; Davis, K.L.; Martin, P.L.; Nemecek, E.R.; Yanik, G.A.; Peters, C.; Baruchel, A.; Boissel, N.; Mechinaud, F.; Balduzzi, A.; Krueger, J.; June, C.H.; Levine, B.L.; Wood, P.; Taran, T.; Leung, M.; Mueller, K.T.; Zhang, Y.; Sen, K.; Lebwohl, D.; Pulsipher, M.A.; Grupp, S.A. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med., 2018, 378(5), 439-448.
[http://dx.doi.org/10.1056/NEJMoa1709866] [PMID: 29385370]

Laetsch, T.W.; Myers, G.D.; Baruchel, A.; Dietz, A.C.; Pulsipher, M.A.; Bittencourt, H.; Buechner, J.; De Moerloose, B.; Davis, K.L.; Nemecek, E.; Driscoll, T.; Mechinaud, F.; Boissel, N.; Rives, S.; Bader, P.; Peters, C.; Sabnis, H.S.; Grupp, S.A.; Yanik, G.A.; Hiramatsu, H.; Stefanski, H.E.; Rasouliyan, L.; Yi, L.; Shah, S.; Zhang, J.; Harris, A.C. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: A global, single-arm, phase 2 trial. Lancet Oncol., 2019, 20(12), 1710-1718.
[http://dx.doi.org/10.1016/S1470-2045(19)30493-0] [PMID: 31606419]

Kerr, W.G.; Chisholm, J.D. The next generation of immunotherapy for cancer: Small molecules could make big waves. J. Immunol., 2019, 202(1), 11-19.
[http://dx.doi.org/10.4049/jimmunol.1800991] [PMID: 30587569]

Kabir, T.F.; Chauhan, A.; Anthony, L.; Hildebrandt, G.C. Immune checkpoint inhibitors in pediatric solid tumors: Status in 2018. Ochsner J., 2018, 18(4), 370-376.
[http://dx.doi.org/10.31486/toj.18.0055] [PMID: 30559623]

Bosse, K.R.; Majzner, R.G.; Mackall, C.L.; Maris, J.M. Immune-based approaches for the treatment of pediatric malignancies. Annu. Rev. Cancer Biol., 2020, 4(1), 353-370.
[http://dx.doi.org/10.1146/annurev-cancerbio-030419-033436] [PMID: 34113750]

Love, V.A.; Grabie, N.; Duramad, P.; Stavrakis, G.; Sharpe, A.; Lichtman, A. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ. Res., 2007, 101(3), 248-257.
[http://dx.doi.org/10.1161/CIRCRESAHA.106.147124] [PMID: 17569889]

Nishimura, H.; Okazaki, T.; Tanaka, Y.; Nakatani, K.; Hara, M.; Matsumori, A.; Sasayama, S.; Mizoguchi, A.; Hiai, H.; Minato, N.; Honjo, T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science, 2001, 291(5502), 319-322.
[http://dx.doi.org/10.1126/science.291.5502.319] [PMID: 11209085]

Rubio-Infante, N.; Ramírez-Flores, Y.A.; Castillo, E.C.; Lozano, O.; García-Rivas, G.; Torre-Amione, G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: A meta‐analysis. Eur. J. Heart Fail., 2021, 23(10), 1739-1747.
[http://dx.doi.org/10.1002/ejhf.2289] [PMID: 34196077]

Salem, J.E.; Manouchehri, A.; Moey, M.; Lebrun-Vignes, B.; Bastarache, L.; Pariente, A.; Gobert, A.; Spano, J.P.; Balko, J.M.; Bonaca, M.P.; Roden, D.M.; Johnson, D.B.; Moslehi, J.J. Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. Lancet Oncol., 2018, 19(12), 1579-1589.
[http://dx.doi.org/10.1016/S1470-2045(18)30608-9] [PMID: 30442497]

Li, C.; Bhatti, S.A.; Ying, J. Immune checkpoint inhibitors—associated cardiotoxicity. Cancers, 2022, 14(5), 1145.
[http://dx.doi.org/10.3390/cancers14051145] [PMID: 35267453]

Hu, J.; Tian, R.; Ma, Y.; Zhen, H.; Ma, X.; Su, Q.; Cao, B. Risk of cardiac adverse events in patients treated with immune checkpoint inhibitor regimens: A systematic review and meta-analysis. Front. Oncol., 2021, 11, 645245.
[http://dx.doi.org/10.3389/fonc.2021.645245] [PMID: 34123795]

Krause, D.S.; Van Etten, R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med., 2005, 353(2), 172-187.
[http://dx.doi.org/10.1056/NEJMra044389] [PMID: 16014887]

Kantarjian, H.; Sawyers, C.; Hochhaus, A.; Guilhot, F.; Schiffer, C.; Gambacorti-Passerini, C.; Niederwieser, D.; Resta, D.; Capdeville, R.; Zoellner, U.; Talpaz, M.; Druker, B.; Goldman, J.; O’Brien, S.G.; Russell, N.; Fischer, T.; Ottmann, O.; Cony-Makhoul, P.; Facon, T.; Stone, R.; Miller, C.; Tallman, M.; Brown, R.; Schuster, M.; Loughran, T.; Gratwohl, A.; Mandelli, F.; Saglio, G.; Lazzarino, M.; Russo, D.; Baccarani, M.; Morra, E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med., 2002, 346(9), 645-652.
[http://dx.doi.org/10.1056/NEJMoa011573] [PMID: 11870241]

Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 2001, 344(14), 1031-1037.
[http://dx.doi.org/10.1056/NEJM200104053441401] [PMID: 11287972]

Druker, B.J.; Guilhot, F.; O’Brien, S.G.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M.W.N.; Silver, R.T.; Goldman, J.M.; Stone, R.M.; Cervantes, F.; Hochhaus, A.; Powell, B.L.; Gabrilove, J.L.; Rousselot, P.; Reiffers, J.; Cornelissen, J.J.; Hughes, T.; Agis, H.; Fischer, T.; Verhoef, G.; Shepherd, J.; Saglio, G.; Gratwohl, A.; Nielsen, J.L.; Radich, J.P.; Simonsson, B.; Taylor, K.; Baccarani, M.; So, C.; Letvak, L.; Larson, R.A. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med., 2006, 355(23), 2408-2417.
[http://dx.doi.org/10.1056/NEJMoa062867] [PMID: 17151364]

Chu, T.F.; Rupnick, M.A.; Kerkela, R.; Dallabrida, S.M.; Zurakowski, D.; Nguyen, L.; Woulfe, K.; Pravda, E.; Cassiola, F.; Desai, J.; George, S.; Harris, D.M.; Ismail, N.S.; Chen, J-H.; Schoen, F.J.; Van den Abbeele, A.D.; Demetri, G.D.; Force, T.; Chen, M.H.; Morgan, J.A. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet, 2007, 370(9604), 2011-2019.
[http://dx.doi.org/10.1016/S0140-6736(07)61865-0] [PMID: 18083403]

Ewer, M.S.; Suter, T.M.; Lenihan, D.J.; Niculescu, L.; Breazna, A.; Demetri, G.D.; Motzer, R.J. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur. J. Cancer, 2014, 50(12), 2162-2170.
[http://dx.doi.org/10.1016/j.ejca.2014.05.013] [PMID: 24930624]

Jain, D.; Russell, R.R.; Schwartz, R.G.; Panjrath, G.S.; Aronow, W. Cardiac complications of cancer therapy: Pathophysiology, identification, prevention, treatment, and future directions. Curr. Cardiol. Rep., 2017, 19(5), 36.
[http://dx.doi.org/10.1007/s11886-017-0846-x] [PMID: 28374177]

Chaar, M.; Kamta, J.; Ait-Oudhia, S. Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities. OncoTargets Ther., 2018, 11, 6227-6237.
[http://dx.doi.org/10.2147/OTT.S170138] [PMID: 30288058]

Motokawa, T.; Ikeda, S.; Ueno, Y.; Eguchi, M.; Minami, T.; Kawano, H.; Kobayashi, K.; Imaizumi, Y.; Maemura, K. Comparison of Dasatinib- and Imatinib-related cardiotoxic adverse events in Japanese patients with chronic myeloid leukemia and gastrointestinal stromal tumor. Circ. Rep., 2022, 4(1), CR-21-CR-0140.
[http://dx.doi.org/10.1253/circrep.CR-21-0140] [PMID: 35083382]

Casavecchia, G.; Spinosa, G.; De Gennaro, L.; Zicchino, S.; Gravina, M.; Magnesa, M.; Di Biase, M.; Brunetti, N.D. Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors. Acta Cardiol., 2022, 77(2), 130-135.
[http://dx.doi.org/10.1080/00015385.2021.1888017] [PMID: 33685352]

Narayan, H.K.; Sheline, K.; Wong, V.; Kuo, D.; Choo, S.; Yoon, J.; Leger, K.; Kutty, S.; Fradley, M.; Tremoulet, A.; Ky, B.; Armenian, S.; Guha, A. Cardiovascular toxicities with pediatric tyrosine kinase inhibitor therapy: An analysis of adverse events reported to the Food and Drug Administration. Pediatr. Blood Cancer, 2023, 70(2), e30059.
[http://dx.doi.org/10.1002/pbc.30059] [PMID: 36385736]